Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine

Nucleosides, Nucleotides & Nucleic Acids
Vijaya L DamarajuZeen Tong

Abstract

The nucleoside analogs 5-azacytidine (azacitidine) and 5-aza-2'-deoxycytidine (decitabine) are active against acute myeloid leukemia and myelodysplastic syndromes. Cellular transport across membranes is crucial for uptake of these highly polar hydrophilic molecules. We assessed the ability of azacitidine, decitabine, and, for comparison, gemcitabine, to interact with human nucleoside transporters (hNTs) in Saccharomyces cerevisiae cells (hENT1/2, hCNT1/2/3) or Xenopus laevis oocytes (hENT3/4). All three drugs inhibited hCNT1/3 potently (K (i) values, 3-26 μM), hENT1/2 and hCNT2 weakly (K (i) values, 0.5-3.1 mM), and hENT3/4 poorly if at all. Rates of transport of [(3)H]gemcitabine, [(14)C]azacitidine, and [(3)H]decitabine observed in Xenopus oocytes expressing individual recombinant hNTs differed substantially. Cytotoxicity of azacitidine and decitabine was assessed in hNT-expressing or hNT-deficient cultured human cell lines in the absence or presence of transport inhibitors where available. The rank order of cytotoxic sensitivities (IC (50) values, μM) conferred by hNTs were hCNT1 (0.1) > hENT1 (0.3) ≫ hCNT2 (8.3), hENT2 (9.0) for azacitidine and hENT1 (0.3) > hCNT1 (0.8) ⋙ hENT2, hCNT2 (>100) for decitabine. Protection again...Continue Reading

References

Apr 15, 1979·Biochemical Pharmacology·R L Momparler, D Derse
Apr 15, 1964·Experientia·F SormJ Veselý
Jan 1, 1966·International Journal of Cancer. Journal International Du Cancer·J VeselýF Sorm
Feb 1, 1982·The Journal of Clinical Investigation·J S WileyA R Paterson
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Jul 3, 2003·Pflügers Archiv : European journal of physiology·Stephen A BaldwinJames D Young
Jul 12, 2003·Pflügers Archiv : European journal of physiology·Jennifer H GrayKathleen M Giacomini
Mar 27, 2004·Nucleosides, Nucleotides & Nucleic Acids·Mark F VickersCarol E Cass
Sep 28, 2004·The Journal of Biological Chemistry·Karen EngelJoanne Wang
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer SpratlinJohn R Mackey
Mar 9, 2007·Cancer Metastasis Reviews·Jing ZhangCarol E Cass
Jan 24, 2009·American Journal of Physiology. Gastrointestinal and Liver Physiology·Rajgopal GovindarajanJashvant D Unadkat
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raphaël MaréchalJean-Luc Van Laethem
Feb 26, 2010·Nucleosides, Nucleotides & Nucleic Acids·Vijaya L DamarajuCarol E Cass
Feb 16, 2011·Expert Opinion on Investigational Drugs·Tadeusz Robak

❮ Previous
Next ❯

Citations

Jun 1, 2013·Nature Reviews. Drug Discovery·Lars Petter JordheimCharles Dumontet
Mar 10, 2015·Molecular Pharmaceutics·Yi CuiJoseph Irudayaraj
Jan 3, 2014·The Journal of Clinical Investigation·Marianne B TreppendahlKirsten Grønbæk
Oct 5, 2012·Expert Opinion on Therapeutic Patents·Jacques FahyPaola B Arimondo
Jan 9, 2015·Drug Metabolism Reviews·Lisa Pleyer, Richard Greil
Aug 4, 2015·Biological & Pharmaceutical Bulletin·Kumiko UedaSeigo Iwakawa
Jul 1, 2015·Experimental Hematology·Clémence LoiseauRaphael Itzykson
Feb 26, 2015·Frontiers in Pharmacology·Marçal Pastor-Anglada, Sandra Pérez-Torras
Jul 20, 2018·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Balázs VaskóPeter Krajcsi
Jun 4, 2019·Therapeutic Advances in Hematology·Angela Gil-Perez, Guillermo Montalban-Bravo
Nov 17, 2019·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ana Bela Sarmento-RibeiroIoannis P Trougakos
Oct 17, 2020·Clinical Pharmacokinetics·Ellen J B Derissen, Jos H Beijnen
Nov 25, 2020·Chemical Reviews·Nicholas J Wright, Seok-Yong Lee
Dec 17, 2021·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Carolina Säll, Christian Fogt Hjorth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.